

What Is Claimed Is:

1. A method of treating or inhibiting urinary incontinence or increased urge to urinate in a mammal, said method comprising administering to said mammal an effective amount of an active compound combination comprising at least one compound selected from group (i) and at least one compound selected from group (ii),

wherein group (i) consists of:

Group a) consisting of:

tramadol, O-demethyltramadol and O-demethyl-N-mono-demethyl-tramadol,


Group b) consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (meperidine)
- tilidine
- tramadol
- viminol
- butorphanol
- dextromoramide
- dezocine
- diacetylmorphine (heroin)
- hydrocodone
- hydromorphone

- ketobemidone
- levomethadone
- levomethadyl acetate (1- α -acetylmethadol (LAAM))
- levorphanol
- morphine
- nalorphine
- oxycodone
- pentazocine
- piritramide
- alfentanil
- buprenorphine
- etorphine
- fentanyl
- remifentanil, and
- sufentanil

Group c) consisting of:

1-phenyl-3-dimethylamino-propane compounds corresponding to formula I



wherein

X is chosen from OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from C₁₋₃-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, R¹ is chosen from C₁₋₄-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, R² and R³ in each case independently of one another are chosen from H or C₁₋₄-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, or

R² and R³ together form a saturated C₄₋₇-cycloalkyl radical, unsubstituted or mono- or polysubstituted, R⁹ to R¹³ in each case independently of one another are chosen from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃ CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted;


where R^{17} and R^{18} in each case independently of one another are chosen from H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted,

or

R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

Group d) consisting of:

substituted 6-dimethylaminomethyl-1-phenylcyclohexane compounds corresponding to formula II



wherein

X is chosen from OH, F, Cl, H or $OC(O)R^7$, where R^7 is chosen from C_{1-3} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, R^1 is chosen from C_{1-4} -alkyl, benzyl, CF_3 , OH, $OCH_2-C_6H_5$, $O-C_{1-4}$ -alkyl, Cl or F and

R^9 to R^{13} in each case independently of one another are chosen from H, F, Cl, Br, I, CH_2F , CHF_2 , CF_3 , OH, SH, OR^{14} , OCF_3 ,

SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted;

where R¹⁷ and R¹⁸ in each case independently of one another are chosen from H; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted,


or

R⁹ and R¹⁰ or R¹⁰ and R¹¹ together form an OCH₂O, OCH₂CH₂O, OCH=CH, CH=CHO, CH=C(CH₃)O, OC(CH₃)=CH, (CH₂)₄ or OCH=CHO ring,

and

Group e) consisting of:

6-dimethylaminomethyl-1-phenyl-cyclohexane compounds corresponding to formula III



III

wherein

X is chosen from OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from C₁₋₃-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, and R⁹ to R¹³ in each case independently of one another are chosen from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted;

where R^{17} and R^{18} in each case independently of one another are chosen from H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted,

or

R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

with the proviso that if R^9 , R^{11} and R^{13} correspond to H and one of R^{10} or R^{12} corresponds to H and the other corresponds to OCH_3 , X may not be OH,

wherein group (ii) consists of:

an anti-muscarine agent selected from the group consisting of: atropine, oxybutinin, propiverine, propantheline, emepronium, trospium, tolterodine, darifenacin and α,α -diphenylacetic acid 4-(N-methylpiperidyl) ester, as well as duloxetine, imipramine and desmopressin,

or a salt of any of the foregoing with a physiologically tolerated acid.

2. The method of claim 1, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a free base.

3. The method of claim 1, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a pure enantiomer or pure diastereoisomer.

4. The method of claim 1, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a mixture of stereoisomers.

5. The method of claim 1, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a racemic mixture.

6. The method of claim 1, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a solvate.

7. The method of claim 1, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a hydrate.

8. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group consisting of:

tramadol, (+)-O-demethyltramadol and (+)-O-demethyl-N-mono-demethyl-tramadol.

9. The method of claim 1, wherein said at least one compound selected from group (i) is (+)-tramadol.

10. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- codeine

- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (meperidine)
- tilidine
- viminol
- butorphanol
- dezocine
- nalorphine
- pentazocine, and
- buprenorphine.

11. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- meptazinol
- nalbuphine
- tilidine, and
- buprenorphine.

12. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

X is chosen from

OH, F, Cl, OC(O)CH₃ or H,

or

R¹ is chosen from

C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched;

or

R² and R³ independently of one another are chosen from

H, C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched;

or

R² and R³ together form a C₅₋₆-cycloalkyl radical, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

or

R⁹ to R¹³, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H, independently of one another are chosen from

H, Cl, F, OH, CF₂H, CF₃ or C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched;

or

R¹² and R¹¹ form a 3,4-OCH=CH ring

or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from:

Cl, F, OH, CF₂H, CF₃, OR¹⁴ or SR¹⁴,

or

if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F,

or

if R^9 , R^{10} , R^{12} and R^{13} correspond to H, R^{11} is chosen from CF_3 , CF_2H , Cl or F,

or

if R^{10} , R^{11} and R^{12} correspond to H, one of R^9 or R^{13} also corresponds to H while the other is chosen from OH, OC_2H_5 or OC_3H_7 .

13. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

X is chosen from OH, F, $OC(O)CH_3$ or H.

14. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

R^1 is chosen from CH_3 , C_2H_5 , C_4H_9 or t-butyl.

15. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

R^2 and R^3 independently of one another are chosen from H, CH_3 , C_2H_5 , i-propyl or t-butyl.

16. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

R^2 and R^3 together form a C_{5-6} -cycloalkyl radical which is saturated and unsubstituted.

17. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:


R^2 and R^3 together form cyclohexyl.

18. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

R^9 to R^{13} , where 3 or 4 of the radicals R^9 to R^{13} must correspond to H, independently of one another are chosen from

H, Cl, F, OH, CF_2H , CF_3 , OCH_3 or SCH_3 .

19. The method of claim 12, wherein compounds corresponding to formula I where $R^3 = H$ are in the form of diastereomers corresponding to formula Ia



and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer

or

are provided as a pure diastereomer

or

compounds corresponding to formula I are provided in the form of the (+)-enantiomer.

20. The method of claim 12, wherein compounds corresponding to formula I, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided as the pure (+)-enantiomer.

21. The method of claim 12, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (2RS,3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
- (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3,4-dichlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3-difluoromethyl-phenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-1-dimethylamino-2-methyl-3-(3-methylsulfanyl-phenyl)-pentan-3-ol,
- (3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-4,4-dimethyl-pentan-3-ol,
- (2RS,3RS)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
- (1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
- (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
- (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
- (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,

- (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
- (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
- (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
- (+)-(1R,2R)-acetic acid 3-dimethylamino-1-ethyl-1-(3-methoxy-phenyl)-2-methyl-propyl ester,
- (1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-1-(3-methoxy-phenyl)-propan-1-ol,
- (2RS,3RS)-3-(4-chlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (+)-(2R,3R)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
- (2RS,3RS)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol and
- (+)-(2R,3R)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol, or

a hydrochloride salt of any of the foregoing.

22. The method of claim 1, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula II wherein:

X is chosen from

OH, F, Cl, OC(O)CH₃ or H,

or

R¹ is chosen from

C₁₋₄-alkyl, CF₃, OH, O-C₁₋₄-alkyl, Cl or F,

or

R⁹ to R¹³, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H, independently of one another are chosen from

H, Cl, F, OH, CF₂H, CF₃ or C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched;
or

R¹² and R¹¹ form a 3,4-OCH=CH ring
or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from:

Cl, F, OH, CF₂H, CF₃, OR¹⁴ or SR¹⁴,

or

if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F,

or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is chosen from CF₃, CF₂H, Cl or F,

or

if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is chosen from OH, OC₂H₅ or OC₃H₇.

23. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

X is chosen from OH, F or H.

24. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

R^1 is chosen from OH, CF_3 or CH_3 .

25. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

R^9 to R^{13} , where 3 or 4 of the radicals R^9 to R^{13} must correspond to H, independently of one another are chosen from


H, Cl, F, OH, CF_2H , CF_3 , OCH_3 or SCH_3 ,

or

if R^9 , R^{11} and R^{13} correspond to H, one of R^{10} or R^{12} also corresponds to H while the other is chosen from:

OH, CF_2H , OR^{14} or SCH_3 .

26. The method of claim 22 wherein the compounds corresponding to formula II are in the form of diastereomers corresponding to formula IIa



IIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer

or

are provided as a pure diastereomer,

or

compounds corresponding to formula II are provided in the form of the (+)-enantiomer.

27. The method of claim 22, wherein compounds corresponding to formula II are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

28. The method of claim 22, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol,
- (1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,2R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methyl-cyclohexyl)-phenol, and
- (1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethyl-cyclohexyl)-phenol, or

a hydrochloride salt of any of the foregoing.

29. The method of claim 1, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula III wherein:

X is chosen from

OH, F, Cl, OC(O)CH₃ or H,

or

R⁹ to R¹³, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H, independently of one another are chosen from

H, Cl, F, OH, CF₂H, CF₃ or C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched;

or

R¹² and R¹¹ form a 3,4-OCH=CH ring

or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from:

Cl, F, OH, SH, CF₂H, CF₃, OR¹⁴ or SR¹⁴,

or

if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F,

or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is chosen from CF₃, CF₂H, Cl or F,

or

if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is chosen from OH, OC₂H₅ or OC₃H₇.

30. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein:

X is chosen from OH, F or H.

31. The method of claim 1, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein:

R^9 to R^{13} , where 3 or 4 of the radicals R^9 to R^{13} must correspond to H, independently of one another are chosen from


H, Cl, F, OH, CF_2H , CF_3 , OCH_3 or SCH_3 ,

or

if R^9 , R^{11} and R^{13} correspond to H, one of R^{10} or R^{12} also corresponds to H while the other is chosen from:

OH, CF_2H , OR^{14} or SCH_3 .

32. The method of claim 29 wherein the compounds corresponding to formula III are in the form of diastereomers corresponding to formula IIIa



IIIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer

or

are provided as a pure diastereomer,

or

compounds corresponding to formula III are provided in the form of the (+)-enantiomer.

33. The method of claim 29, wherein compounds corresponding to formula III, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

34. The method of claim 29, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (+)-(1R,2R)-3-(2-dimethylaminomethyl-1-fluoro-cyclohexyl)-phenol,
- (+)-(1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
- (1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
- (-)-(1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
- (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
- (-)-(1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, and
- (1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, or a hydrochloride salt of any of the foregoing.

35. The method of claim 1, wherein said at least one compound selected from group (ii) is selected from the group consisting of:
darifenacin, duloxetine, oxybutinin and tolterodine.

36. The method of claim 1, wherein said at least one compound selected from group (ii) is selected from the group consisting of:
oxybutinin and tolterodine.

37. A composition of matter comprising as an admixture at least one

compound selected from group (i) and at least one compound selected from group (ii),

wherein group (i) consists of:

Group a) consisting of:

tramadol, O-demethyltramadol or O-demethyl-N-mono-demethyl-tramadol,


Group b) consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (meperidine)
- tilidine
- tramadol
- viminal
- butorphanol
- dextromoramide
- dezocine
- diacetylmorphine (heroin)
- hydrocodone
- hydromorphone
- ketobemidone
- levomethadone
- levomethadyl-acetate (1- α -acetylmethadol (LAAM))
- levorphanol

- morphine
- nalorphine
- oxycodone
- pentazocine
- piritramide
- alfentanil
- buprenorphine
- etorphine
- fentanyl
- remifentanyl
- sufentanyl

Group c) consisting of:

1-phenyl-3-dimethylamino-propane compounds corresponding to formula I



wherein

X is chosen from OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from C₁₋₃-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, R¹ is chosen from C₁₋₄-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

R² and R³ in each case independently of one another are chosen from H or C₁₋₄-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,
or

R² and R³ together form a saturated C₄₋₇-cycloalkyl radical, unsubstituted or mono- or polysubstituted,

R⁹ to R¹³ in each case independently of one another are chosen from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;


where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R¹⁷ and R¹⁸ in each case independently of one another are chosen from H; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted,

or

R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O ,
 OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$,
 $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

Group d) consisting of:

substituted 6-dimethylaminomethyl-1-phenylcyclohexane
 compounds corresponding to formula II



II

wherein

X is chosen from OH, F, Cl, H or $OC(O)R^7$, where R^7 is chosen
 from C_{1-3} -alkyl, branched or unbranched, saturated or
 unsaturated, unsubstituted or mono- or polysubstituted,
 R^1 is chosen from C_{1-4} -alkyl, benzyl, CF_3 , OH, $OCH_2-C_6H_5$, $O-C_{1-4}$ -
 alkyl, Cl or F and

R^9 to R^{13} in each case independently of one another are chosen
 from H, F, Cl, Br, I, CH_2F , CHF_2 , CF_3 , OH, SH, OR^{14} , OCF_3 ,
 SR^{14} , $NR^{17}R^{18}$, $SOCH_3$, $SOCF_3$, SO_2CH_3 , SO_2CF_3 , CN, $COOR^{14}$,
 NO_2 , $CONR^{17}R^{18}$; C_{1-6} -alkyl, branched or unbranched, saturated
 or unsaturated, unsubstituted or mono- or polysubstituted;
 phenyl, unsubstituted or mono- or polysubstituted;


where R^{14} is chosen from C_{1-6} -alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; $PO(O-C_{1-4}\text{-alkyl})_2$, $CO(OC_{1-5}\text{-alkyl})$, $CONH-C_6H_4-(C_{1-3}\text{-alkyl})$, $CO(C_{1-5}\text{-alkyl})$, $CO-CHR^{17}-NHR^{18}$, $CO-C_6H_4-R^{15}$, where R^{15} is ortho- $OCOC_{1-3}$ -alkyl or meta- or para- $CH_2N(R^{16})_2$ where R^{16} is C_{1-4} -alkyl or 4-morpholino, wherein in the radicals R^{14} , R^{15} and R^{16} the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R^{17} and R^{18} in each case independently of one another are chosen from H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted,

or

R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

Group e) consisting of:

6-dimethylaminomethyl-1-phenyl-cyclohexane compounds corresponding to formula III



III

wherein

X is chosen from OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from C₁₋₃-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, and R⁹ to R¹³ in each case independently of one another are chosen from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted;

where R^{17} and R^{18} in each case independently of one another are chosen from H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted,

or

R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

with the proviso that if R^9 , R^{11} and R^{13} correspond to H and one of R^{10} or R^{12} corresponds to H and the other corresponds to OCH_3 , X may not be OH, and

wherein group (ii) consists of:

an anti-muscarine agent selected from the group consisting of: atropine, oxybutinin, propiverine, propantheline, emepronium, trospium, tolterodine, darifenacin and α,α -diphenylacetic acid 4-(N-methylpiperidyl) ester, as well as duloxetine, imipramine and desmopressin,

or a salt of any of the foregoing with a physiologically tolerated acid.

37. The composition of matter of claim 36, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a free base.

38. The composition of matter of claim 36, wherein one or more of said at least one compound selected from group (i) and at least one compound selected

from group (ii) is present in the form of a pure enantiomer or pure diastereoisomer.

39. The composition of matter of claim 36, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a mixture of stereoisomers.

40. The composition of matter of claim 36, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a racemic mixture.

41. The composition of matter of claim 36, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a solvate.

42. The composition of matter of claim 36, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a hydrate.

43. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group consisting of:

tramadol, (+)-O-demethyltramadol and (+)-O-demethyl-N-mono-demethyl-tramadol.

44. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is (+)-tramadol.

45. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (meperidine)
- tilidine
- viminol
- butorphanol
- dezocine
- nalorphine
- pentazocine, and
- buprenorphine.

46. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- meptazinol
- nalbuphine
- tilidine, and

- buprenorphine.

47. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

X is chosen from

OH, F, Cl, OC(O)CH₃ or H,

or

R¹ is chosen from

C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched;

or

R² and R³ independently of one another are chosen from

H, C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched;

or

R² and R³ together form a C₅₋₆-cycloalkyl radical, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

or

R⁹ to R¹³, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H, independently of one another are chosen from

H, Cl, F, OH, CF₂H, CF₃ or C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched;

or

R¹² and R¹¹ form a 3,4-OCH=CH ring

or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from:

Cl, F, OH, CF₂H, CF₃, OR¹⁴ or SR¹⁴,

or

if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F,

or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is chosen from CF₃, CF₂H, Cl or F,

or

if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is chosen from OH, OC₂H₅ or OC₃H₇.

43. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

X is chosen from OH, F, OC(O)CH₃ or H.

49. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

R¹ is chosen from CH₃, C₂H₅, C₄H₉ or t-butyl.

50. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

R² and R³ independently of one another are chosen from H, CH₃, C₂H₅, i-propyl or t-butyl.

51. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

R^2 and R^3 together form a C₅₋₆-cycloalkyl radical which is saturated and unsubstituted.

52. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:


R^2 and R^3 together form cyclohexyl.

53. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

R^9 to R^{13} , where 3 or 4 of the radicals R^9 to R^{13} must correspond to H, independently of one another are chosen from

H, Cl, F, OH, CF₂H, CF₃, OCH₃ or SCH₃.

54. The composition of matter of claim 47, wherein compounds corresponding to formula I where $R^8 = H$ are in the form of diastereomers corresponding to formula Ia



and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer

or

are provided as a pure diastereomer

or

compounds corresponding to formula I are provided in the form of the (+)-enantiomer.

55. The composition of matter of claim 47, wherein compounds corresponding to formula I, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided as the pure (+)-enantiomer.

56. The composition of matter of claim 47, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (2RS,3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
- (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3,4-dichlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3-difluoromethyl-phenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-1-dimethylamino-2-methyl-3-(3-methylsulfanyl-phenyl)-pentan-3-ol,
- (3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-4,4-dimethyl-pentan-3-ol,

- (2RS,3RS)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
 - (1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (+)-(1R,2R)-acetic acid 3-dimethylamino-1-ethyl-1-(3-methoxy-phenyl)-2-methyl-propyl ester,
 - (1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-1-(3-methoxy-phenyl)-propan-1-ol,
 - (2RS,3RS)-3-(4-chlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
 - (+)-(2R,3R)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
 - (2RS,3RS)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol
and
 - (+)-(2R,3R)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol,
- or

a hydrochloride salt of any of the foregoing.

57. The composition of matter of claim 36, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula II wherein:

X is chosen from

OH, F, Cl, OC(O)CH₃ or H,

or

R¹ is chosen from

C₁₋₄-alkyl, CF₃, OH, O-C₁₋₄-alkyl, Cl or F,

or

R⁹ to R¹³, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H, independently of one another are chosen from

H, Cl, F, OH, CF₂H, CF₃ or C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched;

or

R¹² and R¹¹ form a 3,4-OCH=CH ring

or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from:

Cl, F, OH, CF₂H, CF₃, OR¹⁴ or SR¹⁴,

or

if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F,

or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is chosen from CF₃, CF₂H, Cl or F,

or

if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is chosen from OH, OC₂H₅ or OC₃H₇.

58. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

X is chosen from OH, F or H.

59. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

R¹ is chosen from OH, CF₃ or CH₃.

60. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

R⁹ to R¹³, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H, independently of one another are chosen from


H, Cl, F, OH, CF₂H, CF₃, OCH₃ or SCH₃,

or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from:

OH, CF₂H, OR¹⁴ or SCH₃.

61. The composition of matter of claim 57 wherein the compounds corresponding to formula II are in the form of diastereomers corresponding to formula IIa



IIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer

or

are provided as a pure diastereomer,

or

compounds corresponding to formula II are provided in the form of the (+)-enantiomer.

62. The composition of matter of claim 57, wherein compounds corresponding to formula II are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

63. The composition of matter of claim 57, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol,
 - (1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
 - (+)-(1R,2R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methyl-cyclohexyl)-phenol, and
 - (1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethyl-cyclohexyl)-phenol, or
- a hydrochloride salt of any of the foregoing.

64. The composition of matter of claim 36, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula III wherein:

X is chosen from

OH, F, Cl, OC(O)CH₃ or H,

or

R⁹ to R¹³, where 3 or 4 of the radicals R⁹ to R¹³ must correspond to H, independently of one another are chosen from

H, Cl, F, OH, CF₂H, CF₃ or C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched;

or

R¹² and R¹¹ form a 3,4-OCH=CH ring

or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from:

Cl, F, OH, SH, CF₂H, CF₃, OR¹⁴ or SR¹⁴,

or

if R^9 and R^{13} correspond to H and R^{11} corresponds to OH, OCH_3 , Cl or F, one of R^{10} or R^{12} also corresponds to H while the other corresponds to OH, OCH_3 , Cl or F,

or

if R^9 , R^{10} , R^{12} and R^{13} correspond to H, R^{11} is chosen from CF_3 , CF_2H , Cl or F,

or

if R^{10} , R^{11} and R^{12} correspond to H, one of R^9 or R^{13} also corresponds to H while the other is chosen from OH, OC_2H_5 or OC_3H_7 .

65. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein:

X is chosen from OH, F or H.

66. The composition of matter of claim 36, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein:

R^9 to R^{13} , where 3 or 4 of the radicals R^9 to R^{13} must correspond to H, independently of one another are chosen from

H, Cl, F, OH, CF_2H , CF_3 , OCH_3 or SCH_3 ,


or

if R^9 , R^{11} and R^{13} correspond to H, one of R^{10} or R^{12} also corresponds to H while the other is chosen from:

OH, CF_2H , OR¹⁴ or SCH_3 .

67. The composition of matter of claim 64, wherein the compounds corresponding to formula III are in the form of diastereomers corresponding to

formula IIIa



IIIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer

or

are provided as a pure diastereomer,

or

compounds corresponding to formula III are provided in the form of the (+)-enantiomer.

68. The composition of matter of claim 64, wherein compounds corresponding to formula III, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

69. The composition of matter of claim 64, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (+)-(1R,2R)-3-(2-dimethylaminomethyl-1-fluoro-cyclohexyl)-phenol,
- (+)-(1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
- (1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
- (-)-(1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
- (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,

- (-)-(1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, and
- (1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, or a hydrochloride salt of any of the foregoing.

70. The composition of matter of claim 36, wherein said at least one compound selected from group (ii) is selected from the group consisting of: darifenacin, duloxetine, oxybutinin and tolterodine.

71. The composition of matter of claim 36, wherein said at least one compound selected from group (ii) is selected from the group consisting of: oxybutinin and tolterodine.

72. A pharmaceutical formulation comprising as an active compound combination a composition of matter according to claim 36 and suitable additives or auxiliary substances.